EF Hutton initiated coverage of G Medical Innovations with a rating of Buy and set a new price target of $6.00

Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical" or the "Company"), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022. First Half 2022 Financial Results During the six months period ended June 30, 2022, the Company performed over 100,000 tests which includes four types of diagnostic tests –Rapid Antigen, A/B Flu, PCR and Antibody; in connection with these tests, the Company expects to submit approximately

SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13G/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13G/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13G/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13G - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13G - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

SC 13D - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations"), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. ("RSS") to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community.  G Medi

Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations" or the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva. Dear Fellow Shareholders, We are proud to report that at this halfway point of 2023, G Medical has met several significant milestones and is on track to show revenue growth and gain profitability. Our Company has experienced growth in its monitoring services, and we are getting ready to add revenue with our "At Home Test Kits" business unit as we are no

Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the "Notice") from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.

Rehovot, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company") announced today that, on May 11, 2023, the Company received notice from the Hearings Panel (the "Panel") of the Nasdaq Stock Market LLC ("Nasdaq") that the Panel has granted the request of the Company to continue its listing on Nasdaq, subject to the conditions described below. As previously disclosed by the Company, on November 22, 2022, the Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq notifying it that, based on its shareholders' deficit of $1,240 thousand as of June 30, 2022, as reported in the Company's Report of Forei

Rehovot, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company" or "G Medical"), a global leader in next-generation mobile health (mHealth) and digital health, is excited to report that patient enrollment has grown in its home monitoring services by 194% between January and April of 2023, as compared to the same period last year. The increase is due to growing demand for homecare monitoring. As previously announced, in the first quarter of 2023, G Medical signed an agreement with AdventHealth of Central Florida ("AdventHealth"), an operator of 20 hospitals and emergency rooms. AdventHealth experiences on average 5.7 million patient visi

Rehovot, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today announced the closing of its public offering of 12,000,000 ordinary shares (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), each sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 ordinary shares and/or P

Rehovot, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today announced the pricing of an underwritten public offering of 12,000,000 ordinary shares (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each ordinary share (or Pre-Funded Warrant) is being sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to pu

Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company" or "G Medical Innovations"), a global leader in next-generation mobile health (mHealth) and digital health, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with AdventHealth Central Florida ("AdventHealth") to expand the health care system's remote patient monitoring capabilities. Pursuant to the agreement, G Medical Innovations will provide devices to AdventHealth for remote patient monitoring (using the Company's Prizma device), mobile cardiac telemetry (MCT) and extended holter (AECG) monitoring for AdventH

Rehovot, Israel, March 27, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company" or "G Medical Innovations"), a global leader in next-generation mobile health (mHealth) and digital health, and MiCare Path, a leader in optimized patient care through remote patient monitoring, today announced a collaboration to incorporate MiCare Path's solutions and G Medical Innovations' solutions. As part of the collaboration, G Medical Innovations' hardware devices will be integrated with MiCare's software platform and visualization tools to provide remote patient monitoring services. The partnership brings together two innovative companies with a shared vision of tra

Rehovot, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company") announced today that on February 16, 2023, the Company received notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the stockholders' equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the "Equity Rule"), the Company is subject to delisting from Nasdaq unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel").  Accordingly, the Company plans to timely request a hearing before

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

D - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

25-NSE - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)